These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 16879900)

  • 21. Meningococcal group C disease in Greece during 1993-2006: the impact of an unofficial single-dose vaccination scheme adopted by most paediatricians.
    Kafetzis DA; Stamboulidis KN; Tzanakaki G; Kourea Kremastinou J; Skevaki CL; Konstantopoulos A; Tsolia M
    Clin Microbiol Infect; 2007 May; 13(5):550-2. PubMed ID: 17378929
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Commentary: European Medicines Agency recommends approval of a broadly protective vaccine against serogroup B meningococcal disease.
    Granoff DM
    Pediatr Infect Dis J; 2013 Apr; 32(4):372-3. PubMed ID: 23263177
    [No Abstract]   [Full Text] [Related]  

  • 23. From tailor-made to ready-to-wear meningococcal B vaccines: longitudinal study of a clonal meningococcal B outbreak.
    Caron F; du Châtelet IP; Leroy JP; Ruckly C; Blanchard M; Bohic N; Massy N; Morer I; Floret D; Delbos V; Hong E; Révillion M; Berthelot G; Lemée L; Deghmane AE; Bénichou J; Lévy-Bruhl D; Taha MK
    Lancet Infect Dis; 2011 Jun; 11(6):455-63. PubMed ID: 21489881
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The risk of simple febrile seizures after immunisation with a new group B meningococcal vaccine, New Zealand.
    Stehr-Green P; Radke S; Kieft C; Galloway Y; McNicholas A; Reid S
    Vaccine; 2008 Feb; 26(6):739-42. PubMed ID: 18187240
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A multicomponent serogroup B meningococcal vaccine is licensed for use in Europe: what do we know, and what are we yet to learn?
    Martin NG; Snape MD
    Expert Rev Vaccines; 2013 Aug; 12(8):837-58. PubMed ID: 23984957
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neisseria meningitidis serogroup B: laboratory correlates of protection.
    Vermont C; van den Dobbelsteen G
    FEMS Immunol Med Microbiol; 2002 Oct; 34(2):89-96. PubMed ID: 12381458
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In Brief: New meningococcal serogroup B vaccination recommendations.
    Med Lett Drugs Ther; 2020 Nov; 62(1612):191-192. PubMed ID: 33443493
    [No Abstract]   [Full Text] [Related]  

  • 28. The strategy to control New Zealand's epidemic of group B meningococcal disease.
    O'Hallahan J; Lennon D; Oster P
    Pediatr Infect Dis J; 2004 Dec; 23(12 Suppl):S293-8. PubMed ID: 15597072
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Meningococcal serogroup B infections: a search for a broadly protective vaccine.
    Vermont CL; van den Dobbelsteen GP
    Expert Rev Vaccines; 2003 Oct; 2(5):673-81. PubMed ID: 14711328
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Challenges and progress in the development of a serogroup B meningococcal vaccine.
    Lewis S; Sadarangani M; Hoe JC; Pollard AJ
    Expert Rev Vaccines; 2009 Jun; 8(6):729-45. PubMed ID: 19485754
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification by genomic immunization of a pool of DNA vaccine candidates that confer protective immunity in mice against Neisseria meningitidis serogroup B.
    Yero D; Pajón R; Pérez Y; Fariñas M; Cobas K; Diaz D; Solis RL; Acosta A; Brookes C; Taylor S; Gorringe A
    Vaccine; 2007 Jul; 25(28):5175-88. PubMed ID: 17544180
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of a vaccine against serogroup B has been the main scientific challenge. Preface.
    Rappuoli R; Pizza M; Black S; Moxon ER
    Vaccine; 2012 May; 30 Suppl 2():B1-2. PubMed ID: 22607893
    [No Abstract]   [Full Text] [Related]  

  • 33. MeNZB vaccine and epidemic control: when do you stop vaccinating?
    Loring BJ; Turner N; Petousis-Harris H
    Vaccine; 2008 Nov; 26(47):5899-904. PubMed ID: 18804134
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Two meningococcal B vaccines receive FDA 'breakthrough therapy' designation.
    Riedmann EM
    Hum Vaccin Immunother; 2014; 10(6):1428-9. PubMed ID: 25396230
    [No Abstract]   [Full Text] [Related]  

  • 35. Group B meningococcal vaccine science and policy.
    Drysdale SB; Pollard AJ
    J Infect; 2015 Jun; 71 Suppl 1():S15-20. PubMed ID: 25917798
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevention and control of meningococcal outbreaks: The emerging role of serogroup B meningococcal vaccines.
    Oviedo-Orta E; Ahmed S; Rappuoli R; Black S
    Vaccine; 2015 Jul; 33(31):3628-35. PubMed ID: 26093201
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serogroup B meningococcal vaccines-an unfinished story.
    Sadarangani M; Pollard AJ
    Lancet Infect Dis; 2010 Feb; 10(2):112-24. PubMed ID: 20113980
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The concept of "tailor-made", protein-based, outer membrane vesicle vaccines against meningococcal disease.
    Holst J; Feiring B; Naess LM; Norheim G; Kristiansen P; Høiby EA; Bryn K; Oster P; Costantino P; Taha MK; Alonso JM; Caugant DA; Wedege E; Aaberge IS; Rappuoli R; Rosenqvist E
    Vaccine; 2005 Mar; 23(17-18):2202-5. PubMed ID: 15755595
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Outer-membrane-vesicle vaccines: old but not forgotten.
    Stephens DS
    Lancet Infect Dis; 2011 Jun; 11(6):421-2. PubMed ID: 21489883
    [No Abstract]   [Full Text] [Related]  

  • 40. MenB candidate vaccine Bexsero induces robust immune response in infants.
    Riedmann EM
    Hum Vaccin Immunother; 2012 Mar; 8(3):282. PubMed ID: 23213659
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.